Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Abstract Objectives Crizotinib has demonstrated good efficacy in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Continuing crizotinib therapy beyond progressive disease (CBPD) can achieve ongoing survival benefit in real‐world clinical practice. In terms...

Повний опис

Бібліографічні деталі
Автори:	Guangjian Yang, Di Ma, Haiyan Xu, Lu Yang, Junling Li, Puyuan Xing, Xuezhi Hao, Yan Wang
Формат:	Стаття
Мова:	English
Опубліковано:	Wiley 2019-10-01
Серія:	Cancer Medicine
Предмети:	anaplastic lymphoma kinase inhibitor crizotinib crizotinib continuation beyond progressive disease non‐small cell lung cancer treatment duration
Онлайн доступ:	https://doi.org/10.1002/cam4.2420

Схожі ресурси

Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib
за авторством: Carolina Valeria Mahuad, та інші
Опубліковано: (2016-06-01)

Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC
за авторством: Emei GAO, та інші
Опубліковано: (2016-03-01)

The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report
за авторством: Ahmed Badran, та інші
Опубліковано: (2023-08-01)

Treatment of Patients with ALK Gene Rearranged Non-small Cell Lung Cancer  after Resistance to Crizotinib
за авторством: Tao JIANG, та інші
Опубліковано: (2015-02-01)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
за авторством: Moushumi Suryavanshi, та інші
Опубліковано: (2017-01-01)

Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase‐positive non–small cell lung cancer
за авторством: Xiya Ma, та інші
Опубліковано: (2022-06-01)

Crizotinib in treatment of lung cancer
за авторством: Arpita Singh, та інші
Опубліковано: (2017-01-01)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
за авторством: Dennis Christoph Harrer, та інші
Опубліковано: (2020-10-01)

Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer
за авторством: Yuka Kuriyama, та інші
Опубліковано: (2013-08-01)

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
за авторством: Caiyu Lin, та інші
Опубліковано: (2021-12-01)

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center
за авторством: Chang Liu, та інші
Опубліковано: (2019-10-01)

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
за авторством: Chan-Young Ock, та інші
Опубліковано: (2019-09-01)

The Dual Role of Autophagy in Crizotinib-Treated ALK<sup>+</sup> ALCL: From the Lymphoma Cells Drug Resistance to Their Demise
за авторством: Estelle Espinos, та інші
Опубліковано: (2021-09-01)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
за авторством: Muhammad Wasi Alam, та інші
Опубліковано: (2019-07-01)

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
за авторством: Zihua Zou, та інші
Опубліковано: (2022-01-01)

Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report
за авторством: Henan BAI, та інші
Опубліковано: (2021-08-01)

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial
за авторством: Daijiro Harada, та інші
Опубліковано: (2021-03-01)

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
за авторством: Scott N. Gettinger, MD, та інші
Опубліковано: (2022-09-01)

Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea
за авторством: Da Som Jeon, та інші
Опубліковано: (2024-02-01)

Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
за авторством: Tomonobu Koizumi, та інші
Опубліковано: (2016-04-01)

Crizotinib-Associated Renal Cysts: A Case Series
за авторством: Garima Suman, та інші
Опубліковано: (2019-07-01)

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
за авторством: Woo Kyung Ryu, та інші
Опубліковано: (2022-10-01)

A Case of Orbital Metastasis as Disease Progression of Anaplastic Lymphoma Kinase-Positive Lung Cancer Treated with Crizotinib
за авторством: Yoshihiko Sakata, та інші
Опубліковано: (2015-01-01)

Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer
за авторством: Mohieldin A, та інші
Опубліковано: (2018-11-01)

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
за авторством: Di Marino P, та інші
Опубліковано: (2020-03-01)

Molecular epidemiological study of microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene using immunohistochemistry as a cost effective alternative to fluorescence in situ hybridization for Indian patients with adenocarcinoma lung
за авторством: Anurag Mehta, та інші
Опубліковано: (2017-01-01)

Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis
за авторством: Ken Koshikawa, та інші
Опубліковано: (2020-06-01)

Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report
за авторством: Jun Osugi, та інші
Опубліковано: (2016-01-01)

Clinical Efficacy of Crizotinib in Advanced ALK Positive  Non-small Cell Lung Cancer
за авторством: Jing ZHAO, та інші
Опубліковано: (2015-10-01)

Modern treatment of ALK-positive non-small cell lung cancer
за авторством: D. A. Kharagezov, та інші
Опубліковано: (2022-06-01)

Identification of a novel ALK variant intrinsically resistant to crizotinib
за авторством: Ullas Batra, та інші
Опубліковано: (2020-12-01)

Efficacy and Safety of Crizotinib in Advanced or Recurrent  ALK-positive Non-small Cell Lung Cancer
за авторством: Xiaoyan LI, та інші
Опубліковано: (2019-08-01)

Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature
за авторством: Peng Zhang, та інші
Опубліковано: (2024-04-01)

Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL
за авторством: Wanying Liu, та інші
Опубліковано: (2024-02-01)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
за авторством: Yurong Wang, та інші
Опубліковано: (2022-12-01)

Long‐term response to crizotinib in a 17‐year‐old boy with treatment‐naïve ALK‐positive non‐small‐cell lung cancer
за авторством: Giacomina Megaro, та інші
Опубліковано: (2022-03-01)

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study
за авторством: Caicun Zhou, MD, PhD, та інші
Опубліковано: (2024-09-01)

Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib
за авторством: Yuhang Zhou, та інші
Опубліковано: (2023-11-01)

Efficacy of crizotinib therapy for a patient with non-small cell lung cancer with ALK gene rearrangement – case report and review of current therapeutic options
за авторством: Julia Barbara Bargieł, та інші
Опубліковано: (2021-09-01)

A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib
за авторством: Min Zhang, MBBS, та інші
Опубліковано: (2021-02-01)